Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 Mar;150(5):538-40.
doi: 10.1038/sj.bjp.0707132. Epub 2007 Jan 22.

Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase

R C Kukreja  1
Affiliations
Comment

Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase

R C Kukreja. Br J Pharmacol. 2007 Mar.

Abstract

During the past 18 years, sildenafil has evolved from a potential anti-angina drug to an on-demand treatment for erectile dysfunction and more recently to a new orally active treatment for pulmonary hypertension. Recent studies suggest that the drug has powerful cardioprotective effect against ischemia/reperfusion injury, doxorubicin-induced cardiomyopathy and anti-hypertensive effect induced by chronic inhibition of nitric oxide synthase in animals. Based on several recent basic and clinical studies, it is clear that sildenafil and other clinically approved type-5 phosphodiesterase-5 inhibitors including vardenafil and tadalafil will eventually be developed for several cardiovascular indications including essential hypertension, endothelial dysfunction, ischemia/reperfusion injury, myocardial infarction, ventricular remodeling and heart failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cardiovascular protection with PDE-5 inhibitors. See text for description. Abbreviations: RV, right ventricle; LV, left ventricle.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52. - PubMed
    1. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (Viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediat Res. 2005;57:22–27. - PubMed
    1. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274:13729–13732. - PubMed
    1. Das A, Smolenski A, Lohmann SM, Kukreja RC. Cyclic GMP-dependent protein kinase Iá attenuates necrosis and apoptosis following ischemia/reoxygenation in cardiomyocytes. J Biol Chem. 2006;281:38644–38652. - PubMed
    1. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor, sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling. J Biol Chem. 2005;280:12944–12955. - PubMed

Publication types

MeSH terms